A significant number of people with severe COVID-19 carried rare genetic variants in 13 genes known to be critical in the body’s defense against influenza virus, and more than 3.5% were completely missing a functioning gene.
The WHO’s Solidarity trial, a 405-hospital, 30-country open-label randomized trial among 11,266 hospital inpatients, also tested hydroxychloroquine, lopinavir (co-administered with ritonavir) and interferon regimens, which also failed to show effectiveness in hospital inpatients.
The discovery that SARS-CoV-2 virus binds to neuropilin-1—in addition to ACE2—may help explain why the virus is so transmissible compared with other coronaviruses and why it affects so many cells around the body.
Ten years after starting the project, the Human Proteome Organization has completed a 90.4% read of the human proteome, knowledge essential for diagnosing and treating many human diseases and for advancing a more personalized approach to medicine.
Remdesivir—to be marketed in the United States as Veklury—will be indicated for adults and pediatric patients 12 years of age and older who have forms of COVID-19 serious enough to require hospitalization, and who weigh at least 40 kg (88 pounds).
New research corroborates other studies that highlight potential associations between strong MAIT cell activation and severe COVID-19 outcomes and provide important information to help better understand the immune response to SARS-CoV-2 that could help develop new treatments.
According to the new studies, which analyze data from hospitals around the world, about 14% of COVID-19 patients who go on to develop serious illness lack the ability to either make or mount interferons against invading pathogens.
Preliminary findings from a trial involving cancer patients taking immune checkpoint treatment with PD-L1 inhibitors reveal that simultaneous treatment with angiotensin receptor II blockers (ARBs) improve patients’ responses.
There are many connections between oral health and overall health besides diabetes, cardiovascular disease, and arthritis. The researchers’ findings may open a door of understanding for other inflammatory diseases and might even relate to COVID-19.
Researchers based at Kings College in London have discovered that commercially available antibody tests for COVID-19 vary widely in accuracy. The findings also revealed that some fast, lateral flow immunoassay tests, initially assumed to be less accurate, actually produced high quality results.
The ability to generate high-affinity Spike protein binders that block viral interaction with ACE2, but which are highly stable, and small—“to maximize the density of inhibitory domains”—could have multiple advantages over antibodies for direct delivery into the respiratory system.
The study’s authors say that using the assay can lead to earlier detection of PD and, since it can identify patients with early onset of the disease, aid better recruitment for clinical trials.
The IVD controls each provide a complete validation for extraction, amplification, and detection within a molecular assay.
The team sought to determine whether unacylated-ghrelin (AUG) modulated hippocampal plasticity and memory function and whether plasma levels of acyl-ghrelin and UAG were associated with dementia in humans.
The findings suggest that the poor outcome in hospitalized adults with COVID-19 compared to children may not be attributable to a failure to generate adaptive immune responses.
The deep learning model using positron emission tomography/computerized tomography (PET/CT) radiomics may identify which non-small cell lung cancer patients may be sensitive to tyrosine kinase inhibitor treatment and those who would benefit from immune checkpoint inhibitor therapy.
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
AstraZeneca and the University of Oxford resumed the clinical study they paused last week after one U.K. participant developed a “potentially unexplained illness,” while Pfizer and BioNTech have requested FDA approval to add 14,000 participants to their late-stage study.
The conjugate specifically releases the anticancer agent in cancer cells along with a drug-resistance inhibitor to effectively treat cancers without concern over drug resistance.
Researchers have identified potential drug targets and therapies for the three coronaviruses—SARS-CoV-1, SARS-CoV-2, and MERS-CoV. The team hopes that looking at all three viruses will not only help combat the current COVID-19 pandemic, but also to target new coronaviruses that arise in the future.
Researchers at the Karolinska Institute in Sweden have developed a COVID-19 test that bypasses current limitations, without sacrificing accuracy. The test allows quicker, less expensive tests to be conducted in clinical as well as non-clinical settings.
Part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the trial, called ACTIV-1 Immune Modulators (IM), will examine the ability of therapeutic interventions to restore balance in the immune system.
JNJ-78436735 is one of nine COVID-19 vaccine candidates in late-stage clinical trials—and is one of about 200 vaccine candidates in development against SARS-CoV-2 as of October 2, according to the World Health Organization.
University of Vermont researchers found that a species of gut microbiome bacteria called Lactobacillus reuteri—commonly used in probiotics— can increase disease severity in a mouse model of multiple sclerosis (MS), but only in genetically susceptible animals.